AMWatch

EQT byder 6 mia for svenske Karo Pharma

Den svenske kapitalfond EQT har budt knap 6 mia. svenske kroner for det svenske helse- og medicinalselskab Karo Pharma, der for nylig købte 10 lægemidler af Leo Pharma. Aktien stiger med mere end 25 pct.

Photo: /ritzau/Thomas Borberg

Svenske Karo Pharma, der i marts købte ti lægemidler fra Leo Pharma for en samlet pris på 2 mia. kr., er på nippet til at blive solgt til den svenske kapitalfond EQT.

Fonden, der også står bag høreapparatselskabet Sivantos, som snart fusionerer med danske Widex, har således afgivet et tilbud om at købe samtlige aktier i Karo Pharma for 36,90 kr. per stk. svarende til cirka 5,97 mia. svenske kr.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

New paper slams model portfolio boom for conflict of interest

So-called model portfolios -- off-the-shelf investment strategies often comprising bundles of ETFs -- are ridden with conflicts of interest, according a trio of academics, including Associate Professor from the Norwegian School of Economics Nataliya Gerasimova.

Related articles

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch